Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ocugen Inc OCGN

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing... see more

NDAQ:OCGN - Post Discussion

Ocugen Inc > Covaxin got approved. Watch out for OCGN
View:
Post by Khumamayo on Jan 03, 2021 9:22pm

Covaxin got approved. Watch out for OCGN

India has approved the COVID-19 vaccine developed by the University of Oxford and AstraZeneca for emergency use, Information and Broadcasting Minister Prakash Javadekar told reporters Saturday. Additionally, the government authorized the emergency use of a vaccine known as COVAXIN developed locally by Bharat Biotech and the government-run Indian Council of Medical Research
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities